Greater Cannabis Company, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company in a precarious transition, where the scientific potential of its licensed cannabinoid therapy is currently trapped by a catastrophic lack of liquidity. The shift toward neuropsychiatric therapeutics is a clear strategic pivot, but the gap between having a license and executing a Phase II trial is vast and requires capital that the company does not currently possess. The reverse split and debt restructuring were necessary housekeeping measures, but they do not solve the fundamental need for a massive capital infusion. Investors are essentially betting on the ability of CEO Aitan Zacharin to secure a lifeline of funding before the company's negligible cash reserves are entirely depleted. If funding is secured, the company becomes a high-reward speculative play on a breakthrough medical treatment. Without it, the company remains a shell with a going-concern warning and a mounting pile of liabilities. The overall impact of the filing is a reminder that in biotech, a promising license is meaningless without the capital to prove it in the clinic.